312 related articles for article (PubMed ID: 36542670)
1. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
Bell CF; Huang SP; Cyhaniuk A; Averell CM
Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
[TBL] [Abstract][Full Text] [Related]
3. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015.
Hammond ER; Desta B; Near AM; Wang X; Jiang M
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
[TBL] [Abstract][Full Text] [Related]
5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
Lokhandwala T; Coutinho AD; Bell CF
Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
Wu SS; Perry A; Tkacz J; Bryant G
J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
[No Abstract] [Full Text] [Related]
10. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
[TBL] [Abstract][Full Text] [Related]
14. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
Jiang M; Near AM; Desta B; Wang X; Hammond ER
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
[TBL] [Abstract][Full Text] [Related]
15. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
Lokhandwala T; Yue B; Coutinho AD; Bell CF
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany.
Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A
Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212
[TBL] [Abstract][Full Text] [Related]
17. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
Value Health Reg Issues; 2024 Jun; 43():101001. PubMed ID: 38850589
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States.
Dall'Era M; Kalunian K; Eaddy M; Ogbonnaya A; Farrelly E; Turowski E; Birardi V; Solomons N; Randhawa S; Mina-Osorio P
J Manag Care Spec Pharm; 2023 Jan; 29(1):36-45. PubMed ID: 36190835
[No Abstract] [Full Text] [Related]
19. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
[TBL] [Abstract][Full Text] [Related]
20. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.
Khamashta MA; Bruce IN; Gordon C; Isenberg DA; Ateka-Barrutia O; Gayed M; Donatti C; Guillermin AL; Foo J; Perna A
Lupus; 2014 Mar; 23(3):273-83. PubMed ID: 24356612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
